Evidence map›Paper›PMID 34865514›Full record

ArticleCirculation. Heart failure2022

FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure.

Salah Sommakia, Naredos H Almaw, Sandra H Lee, Dinesh K A Ramadurai, Iosif Taleb, Christos P Kyriakopoulos, Chris J Stubben, Jing Ling, Robert A Campbell, Rami A Alharethi and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation. Heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025
    Review
  9. The Cardiohepatic Axis in Metabolic Disease: Liver to Heart.JACC. Basic to translational science · 2025
    Review
  10. Article
  11. Clinical Insights from Proteomics in Heart Failure.Current heart failure reports · 2025
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Salah SommakiaNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Naredos H AlmawNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.ORCID 0000-0003-3933-8175
Sandra H LeeNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Dinesh K A RamaduraiNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Iosif TalebNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Christos P KyriakopoulosNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Chris J StubbenBioinformatics Shared Resource, Huntsman Cancer Institute (C.J.S.), University of Utah, Salt Lake City.
Jing LingNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Robert A CampbellDivision of General Medicine, Department of Internal Medicine, Program in Molecular Medicine (R.A.C.), University of Utah, Salt Lake City.ORCID 0000-0003-0027-694X
Rami A AlharethiUtah Transplant Affiliated Hospitals Cardiac Transplant Program, University of Utah Healthcare and School of Medicine, Intermountain Medical Center, Salt Lake Veterans Affairs Health Care System (R.A.A., W.T.C., C.H.S., S.G.D., J.C.F.).
William T CaineUtah Transplant Affiliated Hospitals Cardiac Transplant Program, University of Utah Healthcare and School of Medicine, Intermountain Medical Center, Salt Lake Veterans Affairs Health Care System (R.A.A., W.T.C., C.H.S., S.G.D., J.C.F.).ORCID 0000-0002-2064-6904
Sutip NavankasattusasNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Guillaume L HoareauDivision of Emergency Medicine (G.L.H.), University of Utah, Salt Lake City.ORCID 0000-0002-8635-3960
Anu E AbrahamDepartment of Surgery and Division of Cardiovascular Medicine, Department of Internal Medicine (A.E.A., J.C.F., S.G.D., D.C.), University of Utah, Salt Lake City.
James C FangDepartment of Surgery and Division of Cardiovascular Medicine, Department of Internal Medicine (A.E.A., J.C.F., S.G.D., D.C.), University of Utah, Salt Lake City.
Craig H SelzmanNora Eccles Harrison Cardiovascular Research and Training Institute (S.S., N.H.A., S.H.L., D.K.A.R., I.T., C.P.K., J.L., S.N., G.L.H., C.H.S., S.G.D., D.C.), University of Utah, Salt Lake City.
Stavros G DrakosDepartment of Surgery and Division of Cardiovascular Medicine, Department of Internal Medicine (A.E.A., J.C.F., S.G.D., D.C.), University of Utah, Salt Lake City.
Dipayan ChaudhuriDepartment of Surgery and Division of Cardiovascular Medicine, Department of Internal Medicine (A.E.A., J.C.F., S.G.D., D.C.), University of Utah, Salt Lake City.ORCID 0000-0003-0605-7334
Norwegian Womens Public Health Association · NOIntermountain Healthcare · USUniversity of Utah · USHuntsman Cancer Institute · US

Funding

TRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6M
Vascular Health and Risk Factors in Children with Down SyndromeKL2TR002539 · NCATS · UNIVERSITY OF UTAH · PI MURTAUGH, MAUREEN A, NYGAARD, INGRID E · 2018 to 2022
$4.3M
Metabolic Impact and Mechanism of Enhanced Mitochondrial Calcium Uptake in Mitochondrial CardiomyopathiesR01HL141353 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Dipayan Chaudhuri · 2018 to 2026
$4.3M
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart FailureR01HL135121 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE · 2017 to 2021
$1.9M
Cellular Remodeling in Heart Failure and after LVAD UnloadingR01HL132067 · NHLBI · UNIVERSITY OF UTAH · PI DRAKOS, STAVROS GEORGE, SACHSE, FRANK BERND · 2017 to 2020
$1.5M
Understanding Myocardial Recovery in Diabetes and Heart FailureI01CX002291 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI DRAKOS, STAVROS GEORGE · 2021 to 2025
–
CSRD VA I01 CX002291NCATS NIH HHS KL2 TR002539NHLBI NIH HHS R01 HL132067NHLBI NIH HHS R01 HL135121NHLBI NIH HHS R01 HL141353NHLBI NIH HHS T32 HL007576
6 · The paper itself

Abstract

backgroundExtrinsic control of cardiomyocyte metabolism is poorly understood in heart failure (HF). FGF21 (Fibroblast growth factor 21), a hormonal regulator of metabolism produced mainly in the liver and adipose tissue, is a prime candidate for such signaling.

methodsTo investigate this further, we examined blood and tissue obtained from human subjects with end-stage HF with reduced ejection fraction at the time of left ventricular assist device implantation and correlated serum FGF21 levels with cardiac gene expression, immunohistochemistry, and clinical parameters.

resultsCirculating FGF21 levels were substantially elevated in HF with reduced ejection fraction, compared with healthy subjects (HF with reduced ejection fraction: 834.4 [95% CI, 628.4-1040.3] pg/mL, n=40; controls: 146.0 [86.3-205.7] pg/mL, n=20,

conclusionsCirculating FGF21 levels are elevated in HF with reduced ejection fraction and appear to bind to the heart. The liver is likely the main extracardiac source. This supports a model of hepatic FGF21 communication to diseased cardiomyocytes, defining a potential cardiohepatic signaling circuit in human HF.

Indexed as

Fibroblast Growth FactorsHeart FailureVentricular Dysfunction, LeftHumansNatriuretic Peptide, Brainfibroblast growth factor 21Fibroblast Growth FactorsNatriuretic Peptide, Brainbilirubinfibroblast growth factorketonesmetabolismnatriuretic peptides

Identifiers

PMID34865514
PMCPMC8930477
OpenAlexW4200142146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.